blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3473648

EP3473648 - HUMAN ANTIBODIES TO PD-L1 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.04.2022
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  30.04.2021
FormerGrant of patent is intended
Status updated on  10.12.2020
FormerRequest for examination was made
Status updated on  13.11.2020
FormerGrant of patent is intended
Status updated on  27.07.2020
FormerRequest for examination was made
Status updated on  04.10.2019
FormerThe application has been published
Status updated on  22.03.2019
Most recent event   Tooltip03.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 05.06.2024  [2024/23]
Applicant(s)For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
[2019/17]
Inventor(s)01 / PAPADOPOULOS, Nicholas, J.
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
02 / MURPHY, Andrew, J.
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
03 / THURSTON, Gavin
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
04 / IOFFE, Ella
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
05 / BUROVA, Elena
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
 [2019/17]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2021/22]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2019/17]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date18206830.423.01.2015
[2019/17]
Priority number, dateUS201461930582P23.01.2014         Original published format: US 201461930582 P
US201462089549P09.12.2014         Original published format: US 201462089549 P
[2019/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3473648
Date:24.04.2019
Language:EN
[2019/17]
Type: B1 Patent specification 
No.:EP3473648
Date:02.06.2021
Language:EN
[2021/22]
Search report(s)(Supplementary) European search report - dispatched on:EP11.02.2019
ClassificationIPC:C07K16/28, C07K16/30, A61K39/395, C07K16/22, A61P35/00, A61P31/14, A61P31/18, A61P31/20, A61P37/02, // A61K39/00
[2021/01]
CPC:
C07K16/2827 (EP,EA,KR,US); A61K39/3955 (EA,KR,US); A61K39/39558 (EP,EA,KR,US);
A61K45/06 (EA,KR,US); A61P31/14 (EP); A61P31/18 (EP);
A61P31/20 (EP); A61P35/00 (EP); A61P37/02 (EP);
C07K16/22 (EP,EA,KR,US); C07K16/30 (EP,EA,KR,US); A61K2039/505 (EP,EA,US);
A61K2039/507 (EP,EA,US); C07K2317/21 (EP,EA,KR,US); C07K2317/565 (EA,KR,US);
C07K2317/75 (EP,EA,KR,US); C07K2317/76 (EP,EA,KR,US); C07K2317/92 (EP,EA,KR,US) (-)
C-Set:
A61K39/39558, A61K2300/00 (EP,US)
Former IPC [2019/17]C07K16/28, C07K16/30, A61K39/395, C07K16/22, A61P35/00, // A61K39/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/45]
Former [2019/17]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA30.09.2019
ME30.09.2019
TitleGerman:MENSCHLICHE ANTIKÖRPER GEGEN PD-L1[2019/17]
English:HUMAN ANTIBODIES TO PD-L1[2019/17]
French:ANTICORPS HUMAINS DIRIGÉS CONTRE PD-L1[2019/17]
Examination procedure30.09.2019Examination requested  [2019/45]
30.09.2019Date on which the examining division has become responsible
01.10.2019Amendment by applicant (claims and/or description)
28.07.2020Communication of intention to grant the patent
05.11.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
11.12.2020Communication of intention to grant the patent
20.04.2021Fee for grant paid
20.04.2021Fee for publishing/printing paid
20.04.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP15703380.4  / EP3097120
Opposition(s)03.03.2022No opposition filed within time limit [2022/19]
Fees paidRenewal fee
16.11.2018Renewal fee patent year 03
16.11.2018Renewal fee patent year 04
16.11.2018Renewal fee patent year 05
21.01.2020Renewal fee patent year 06
20.01.2021Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL02.06.2021
EE02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
MK02.06.2021
RO02.06.2021
RS02.06.2021
SI02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
IS02.10.2021
LU23.01.2022
[2024/23]
Former [2022/46]AL02.06.2021
EE02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
RO02.06.2021
RS02.06.2021
SI02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
IS02.10.2021
LU23.01.2022
Former [2022/29]AL02.06.2021
EE02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
RO02.06.2021
RS02.06.2021
SI02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
IS02.10.2021
Former [2022/26]AL02.06.2021
EE02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
RO02.06.2021
RS02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
IS02.10.2021
Former [2022/10]EE02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
RO02.06.2021
RS02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
IS02.10.2021
Former [2022/07]HR02.06.2021
LT02.06.2021
LV02.06.2021
RS02.06.2021
SM02.06.2021
BG02.09.2021
Former [2021/51]HR02.06.2021
LT02.06.2021
LV02.06.2021
RS02.06.2021
BG02.09.2021
Former [2021/49]HR02.06.2021
LT02.06.2021
LV02.06.2021
BG02.09.2021
Former [2021/46]LT02.06.2021
BG02.09.2021
Documents cited:Search[I] WO2010077634  (GENENTECH INC et al.)
by applicantUS7943742
 US8383796
 US8217149
 US2009055944
 US2012003056
 US2013034559
 US2013045200
 US2013045201
 US2013045202
 WO2007005874
 WO2011066389
 WO2010077634
 EP1907424
 EP1899379
 US6596541
 US201414170166
 US2004101920
 WO2005103081
 US201113022759
 US2010331527
 US8257740
 US8246995
 US7087411
 US2007280945
 US2014088295
 US2010203056
   DONG ET AL., NATURE MED., 1999
   CHEN ET AL., NATURE REV. IMMUNOL., vol. 13, 2013, pages 227 - 242
   FREEMAN, PNAS, vol. 105, 2008, pages 10275 - 10276
   FRANCISCO ET AL., IMMUNOL. REV., vol. 236, 2010, pages 219 - 242
   RIBAS, NEJM, vol. 366, 2012, pages 2517 - 2519
   SHERIDAN, NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 729 - 730
   REDDY ET AL., J. IMMUNOL., vol. 164, 2000, pages 1925 - 1933
   KABAT: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH
   AL-LAZIKANI ET AL., J. MOL. BIOI., vol. 273, 1997, pages 927 - 948
   MARTIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 9268 - 9272
   SHIELD ET AL., JBC, vol. 277, 2002, pages 26733
   "GenBank", Database accession no. NP_054862.1
   "GenBank", Database accession no. NP _005009.2
   "GenBank", Database accession no. NP_005182.1
   PADLAN ET AL., FASEB J., vol. 9, 1995, pages 133 - 139
   VAJDOS ET AL., J MOL BIOL, vol. 320, 2002, pages 415 - 428
   PEARSON, METHODS MOL. BIOL., vol. 24, 1994, pages 307 - 331
   GONNET ET AL., SCIENCE, vol. 256, 1992, pages 1443 45
   ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
   NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
   LLOYD, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999
   HARLOW; LANE: "Antibodies", COLD SPRING HARBOR PRESS
   REINEKE, METHODS MOL. BIOL., vol. 248, 2004, pages 443 - 63
   TOMER, PROT. SCI., vol. 9, 2000, pages 487 - 496
   EHRING, ANALYTICAL BIOCHEMISTRY, vol. 267, 1999, pages 252 - 259
   ENGEN; SMITH, ANAL. CHEM., vol. 73, 2001, pages 256A - 265A
   JUNGHANS ET AL., CANCER RES., vol. 50, 1990, pages 1495 - 1502
   TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60 - 69
   KUFER ET AL., TRENDS BIOTECHNOL, vol. 22, 2004, pages 238 - 244
   KLEIN, MABS, vol. 4, no. 6, 2012, pages 1 - 11
   KAZANE ET AL., J. AM. CHEM. SOC., 4 December 2012 (2012-12-04)
   POWELL ET AL.: "Compendium of excipients for parenteral formulations", J PHARM SCI TECHNOL, vol. 52, 1998, pages 238 - 311, XP009119027
   WU ET AL., J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432
   LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
   ARRUEBO, M. ET AL.: "Antibody-conjugated nanoparticles for biomedical applications", J. NANOMAT., vol. 2009, 2009, pages 24
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.